BIOS Capital Management, LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 18, 2025), BIOS Capital Management, LP reported 6 stock positions worth $94.1 million. Its top holding was Actuate Therapeutics (ACTU) at 83.7% of the portfolio, followed by Cognition Therapeutics (CGTX, 4.5%) and Rein Therapeutics (RNTX, 4.1%).
- Most Recent 13F
- Q2 2026
- Location
- Fort Worth, TX
- CIK
- 0001813845
- Portfolio Value
- $94.1M (Q4 2024)
- SEC Filing
- 0001104659-25-014450 ↗ filed Feb 18, 2025
Holdings Value
Holdings 6 stocks · $94.1M
| ACTU Actuate Therapeutics Inc. | 83.69% | 9,893,651 | $78.8M | — |
| CGTX Cognition Therapeutics Inc. | 4.47% | 6,000,000 | $4.2M | — |
| RNTX Rein Therapeutics Inc. filed as AILERON THERAPEUTICS INC | 4.13% | 1,690,751 | $3.9M | — |
| LTRN Lantern Pharma Inc. | 4.09% | 1,207,709 | $3.9M | — |
| INAB IN8BIO Inc. | 2.35% | 8,600,001 | $2.2M | — |
| IRD Opus Genetics Inc. | 1.26% | 995,249 | $1.2M | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $41.7M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q1 2026 | 6 | $52.9M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q4 2025 | 6 | $82.6M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q3 2025 | 6 | $88.9M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q2 2025 | 6 | $72.6M | ACTU, IRD, LTRN, RNTX, CGTX |
| Q1 2025 | 6 | $79.2M | ACTU, LTRN, RNTX, CGTX, INAB |
| Q4 2024Amended | 6 | $94.1M | ACTU, CGTX, RNTX, LTRN, INAB |